CRL · Charles River Laboratories International, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $995.83M | - | $1.00B | $1.03B | $984.17M | - | $1.01B | $1.03B | $1.01B | - |
| Cost of Revenue | - | - | - | - | - | - | $664.78M | $660.96M | $651.72M | - |
| Gross Profit | - | - | - | - | - | - | $344.98M | $365.16M | $359.84M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $159.42M | - | $177.59M | $191.55M | $177.80M | - | $199.21M | $169.79M | $186.29M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $67.15M | - | $85.16M | $119.51M | $120.36M | - | $88.20M | $86.08M | $85.36M | - |
| Operating Income | $119.90M | - | $133.80M | $100.13M | $74.67M | - | $117.41M | $151.65M | $125.98M | - |
| Interest Expense | $26.74M | - | $25.40M | $29.97M | $27.88M | - | $33.74M | $32.77M | $35.00M | - |
| Income Tax | ($15.14M) | - | $31.64M | $18.73M | $10.10M | - | $20.95M | $25.39M | $24.53M | - |
| Net Income | ($14.84M) | - | $54.42M | $52.33M | $25.47M | - | $69.66M | $94.08M | $72.96M | - |
| EPS - Basic | ($0.30) | - | $1.11 | $1.06 | $0.50 | - | $1.34 | $1.75 | $1.31 | - |
| EPS - Diluted | ($0.30) | - | $1.10 | $1.06 | $0.50 | - | $1.33 | $1.74 | $1.30 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $191.83M | $213.77M | $207.10M | $182.82M | $229.36M | $194.61M | $210.17M | $179.21M | $327.04M | $276.77M |
| Accounts Receivable | $700.25M | $708.86M | $734.48M | $767.57M | $756.63M | $720.91M | $754.21M | $762.22M | $786.98M | $780.38M |
| Inventory | $359.72M | $299.10M | $302.55M | $279.55M | $290.16M | $278.54M | $336.20M | $349.11M | $361.28M | $380.26M |
| Accounts Payable | $133.95M | $148.80M | $169.62M | $145.80M | $149.33M | $140.34M | $135.96M | $133.10M | $129.68M | $168.94M |
| Current Assets | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B | $1.67B | $1.61B |
| Total Assets | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | $8.20B |
| Current Liabilities | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994.10M | $1.01B | $947.52M | $954.81M | $1.06B |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | $4.54B |
| Stockholders' Equity | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B | $3.64B | $3.60B |
| Retained Earnings | $1.37B | $1.39B | $1.94B | $1.89B | $1.84B | $1.81B | $2.12B | $2.05B | $1.96B | $1.89B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $41.08M | - | - | - | $171.70M | - | - | - | $129.89M | - |
| Investing Cash Flow | ($407.85M) | - | - | - | ($45.48M) | - | - | - | ($85.79M) | - |
| Financing Cash Flow | $347.72M | - | - | - | ($105.33M) | - | - | - | $18.35M | - |
| CapEx | $55.91M | - | $35.58M | $35.30M | $59.32M | - | $38.72M | $39.49M | $79.14M | - |
| Free Cash Flow | ($14.83M) | - | - | - | $112.37M | - | - | - | $50.74M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | 34.2% | 35.6% | 35.6% | - |
| Operating margin | 12.0% | - | 13.3% | 9.7% | 7.6% | - | 11.6% | 14.8% | 12.5% | - |
| EBITDA margin | 18.8% | - | 21.8% | 21.3% | 19.8% | - | 20.4% | 23.2% | 20.9% | - |
| Net margin | -1.5% | - | 5.4% | 5.1% | 2.6% | - | 6.9% | 9.2% | 7.2% | - |
| Free cash flow margin | -1.5% | - | - | - | 11.4% | - | - | - | 5.0% | - |
| FCF / Net income | 1.00 | - | - | - | 4.41 | - | - | - | 0.70 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 16.0% | - | 17.7% | 18.6% | 18.1% | - | 19.7% | 16.5% | 18.4% | - |
| Effective tax rate | - | - | 36.8% | 26.4% | 28.4% | - | 23.1% | 21.3% | 25.2% | - |
| Return on assets | -0.2% | - | 0.7% | 0.7% | 0.3% | - | 0.9% | 1.2% | 0.9% | - |
| Return on equity | -0.5% | - | 1.6% | 1.6% | 0.8% | - | 1.8% | 2.5% | 2.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.36 | 1.29 | 1.37 | 1.36 | 1.43 | 1.41 | 1.48 | 1.58 | 1.75 | 1.52 |
| Quick ratio | 1.03 | 1.02 | 1.10 | 1.10 | 1.16 | 1.13 | 1.14 | 1.21 | 1.37 | 1.16 |
| Cash ratio | 0.18 | 0.19 | 0.18 | 0.17 | 0.22 | 0.20 | 0.21 | 0.19 | 0.34 | 0.26 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 4.5x | - | 5.3x | 3.3x | 2.7x | - | 3.5x | 4.6x | 3.6x | - |
| Equity multiplier | 2.63 | 2.25 | 2.21 | 2.25 | 2.37 | 2.17 | 2.12 | 2.14 | 2.24 | 2.28 |
| Liabilities / Assets | 0.61 | 0.55 | 0.54 | 0.55 | 0.57 | 0.53 | 0.52 | 0.53 | 0.55 | 0.55 |
| Efficiency | ||||||||||
| Asset turnover | 0.13 | - | 0.13 | 0.14 | 0.13 | - | 0.13 | 0.13 | 0.12 | - |
| Inventory turnover | - | - | - | - | - | - | 1.98 | 1.89 | 1.80 | - |
| Days sales outstanding | 257d | - | 267d | 271d | 281d | - | 273d | 271d | 284d | - |
| Days inventory outstanding | - | - | - | - | - | - | 185d | 193d | 202d | - |
| Days payable outstanding | - | - | - | - | - | - | 75d | 74d | 73d | - |
| Cash conversion cycle | - | - | - | - | - | - | 383d | 390d | 414d | - |
| Valuation | ||||||||||
| P / E | - | - | 135.1x | 141.5x | 311.1x | - | 149.1x | 118.7x | 208.4x | - |
| P / B | 2.6x | - | 2.2x | 2.2x | 2.5x | - | 2.7x | 2.9x | 3.9x | - |
| P / S | 7.8x | - | 7.3x | 7.2x | 8.0x | - | 10.1x | 10.4x | 13.9x | - |
| EV / EBITDA | 40.6x | - | 32.6x | 32.8x | 39.4x | - | 48.7x | 44.3x | 64.9x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 1.2% | - | -0.5% | 0.6% | -2.7% | - | -1.6% | -3.2% | -1.7% | - |
| Revenue CAGR (3y) | -1.1% | - | 0.5% | 2.0% | 2.5% | - | 4.1% | 3.9% | 7.1% | - |
| Revenue CAGR (5y) | 3.8% | - | 6.2% | 8.6% | 6.8% | - | 8.6% | 9.3% | 10.8% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 60.6% | - | 14.0% | -34.0% | -40.7% | - | -22.5% | -8.1% | -25.0% | - |
| Net income growth (YoY) | - | - | -21.9% | -44.4% | -65.1% | - | -20.3% | -3.0% | -29.3% | - |
| EPS growth (YoY) | - | - | -17.3% | -39.1% | -61.5% | - | -21.3% | -7.9% | -35.3% | - |
| EPS CAGR (3y) | - | - | -16.4% | -20.8% | -34.9% | - | -12.9% | 0.4% | 2.7% | - |
| EPS CAGR (5y) | - | - | -11.5% | -4.6% | -13.3% | - | -1.8% | 14.6% | 3.2% | - |
| FCF growth (YoY) | - | - | - | - | 121.5% | - | - | - | 1923.3% | - |
| FCF CAGR (5y) | - | - | - | - | 21.3% | - | - | - | 3.2% | - |
| Book value growth (YoY) | -7.9% | -8.6% | -10.0% | -9.9% | -12.3% | -3.8% | 14.4% | 14.5% | 17.1% | 20.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-27.
Business segments
$3.17B totalDiscovery And Safety Assessment Segment$2.40B · 75.6%
Research Models And Services Segment$389.09M · 12.3%
Manufacturing Support Segment$383.68M · 12.1%
Product / service
$4.02B totalService$3.25B · 80.9%
Product$765.28M · 19.1%
Geographic
$4.02B totalUS$2.14B · 53.3%
Europe$1.10B · 27.5%
CA$501.02M · 12.5%
Asia Pacific$205.02M · 5.1%
Other$64.86M · 1.6%
Peer comparison
Same SIC group: Services-Commercial Physical & Biological Research
Comparing CHARLES RIVER LABORATORIES INTERNATIONAL against the 5 most active filers in the same SIC group.